» Articles » PMID: 14981514

Bystander Elimination of Antigen Loss Variants in Established Tumors

Overview
Journal Nat Med
Date 2004 Feb 26
PMID 14981514
Citations 128
Authors
Affiliations
Soon will be listed here.
Abstract

Cancers express antigens that are targets for specific cytotoxic T lymphocytes (CTLs). However, cancer cells are genetically unstable. Consequently, sub-populations of cancer cells that no longer express the target antigen may escape destruction by CTLs and grow progressively. We show that cytotoxic T cells indirectly eliminate these antigen loss variants (ALVs) in a model system when the parental cancer cells express sufficient antigen to be effectively cross-presented by the tumor stroma. When the parental tumor expressed lower levels of antigen, cytotoxic T cells eradicated the antigen-positive parental cancer cells, but the ALVs escaped, grew and killed the host. By contrast, when the parental tumor expressed higher levels of antigen, cytotoxic T cells eradicated not only the parental cancer cells but also the ALVs. This 'bystander' elimination of ALVs required stromal cells expressing major histocompatibility complex (MHC) molecules capable of presenting the antigen, and occurred in tumors showing evidence of stromal destruction. ALVs were apparently eliminated indirectly when tumor-specific CTLs killed stromal cells that were cross-presenting antigen produced by and released from antigen-positive cancer cells. These results highlight the general importance of targeting the tumor stroma to prevent the escape of variant cancer cells.

Citing Articles

CD4 T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy.

Wolf S, Leisegang M, Steiner M, Wallace V, Kiyotani K, Hu Y Sci Immunol. 2024; 9(99):eadp6529.

PMID: 39270007 PMC: 11560124. DOI: 10.1126/sciimmunol.adp6529.


Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma.

Sun B, Zhang D, Gan W, Wu J, Wang Z, Sun G J Cancer Res Clin Oncol. 2024; 150(7):348.

PMID: 39002018 PMC: 11246275. DOI: 10.1007/s00432-024-05869-1.


Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy.

Lischer C, Eberhardt M, Flamann C, Berges J, Guse E, Wessely A J Immunother Cancer. 2024; 12(5).

PMID: 38724462 PMC: 11086525. DOI: 10.1136/jitc-2023-008104.


Distinct spatiotemporal dynamics of CD8 T cell-derived cytokines in the tumor microenvironment.

Hoekstra M, Slagter M, Urbanus J, Toebes M, Slingerland N, de Rink I Cancer Cell. 2024; 42(1):157-167.e9.

PMID: 38194914 PMC: 10783802. DOI: 10.1016/j.ccell.2023.12.010.


Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.

Plewa N, Poncette L, Blankenstein T J Immunother Cancer. 2023; 11(2).

PMID: 36822673 PMC: 9950979. DOI: 10.1136/jitc-2022-006001.